Organization · Venture Capital
BrightEdge - American Cancer Society
BrightEdge is the innovation and impact investment arm of the American Cancer Society, focusing on early-stage investments in companies developing cancer therapeutics, diagnostics, and technologies. It aims to bridge funding gaps and enhance patient-centric solutions in cancer care.
Overview
What BrightEdge - American Cancer Society does
What BrightEdge - American Cancer Society is
BrightEdge is the innovation and impact investment arm of the American Cancer Society, focusing on early-stage investments in companies developing cancer therapeutics, diagnostics, and technologies. It aims to bridge funding gaps and enhance patient-centric solutions in cancer care.
How it participates in the startup ecosystem
The current public profile supports funder and event host and publisher capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2018
- Approximate age
- About 8 years
- Structured capabilities
- Funder · Event host · Publisher
- Last reviewed
- April 22, 2026
Official channels
Find BrightEdge - American Cancer Society elsewhere
Open the official website or a supported primary organization account.
Capability profile
BrightEdge - American Cancer Society as a funder
Investment thesis
BrightEdge focuses on cancer-focused innovation across therapeutics, diagnostics, devices, and digital health, guided by 10 ACS mission priority areas. Investments are evaluated for their potential patient impact, not purely financial returns.
Focus narrative
BrightEdge invests in early-stage companies and technologies that provide patient-centric solutions in cancer care. Their strategy includes advancing scientific discovery, reducing health disparities, and building sustainability through strategic investments in technology-enabled solutions and science-based medicines.
Value beyond capital
BrightEdge provides ongoing support to portfolio companies, aiming to generate financial returns that diversify ACS's funding sources. They also offer mentorship and resources through initiatives like the Project HEALTH accelerator, which targets startups addressing cancer care disparities.
Terms and economics
- Typical check
- $50,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 16
Portfolio context
BrightEdge supports pioneering start-up companies in cancer care, with an active portfolio of 16 companies as of 2024. They have deployed $52M in 22 companies since inception, focusing on innovations that enhance patient outcomes and access to care.
Capability profile
BrightEdge - American Cancer Society as an event host
Event focus
BrightEdge invests in for-profit, early-stage companies developing cancer-focused therapeutics, diagnostics, devices, and technologies. The organization aims to accelerate the commercialization of patient-centric innovations across the cancer care continuum, particularly in prevention, early detection, patient access, affordability, care breakthroughs, and treatment adherence.
Format narrative
BrightEdge hosts various programs and events, including the BrightEdge Entrepreneurs Program and the BEE Pitch Event, aimed at supporting early-stage cancer-fighting entrepreneurs and connecting oncology stakeholders with startup teams.
Participant value
BrightEdge provides funding, mentorship, and resources to early-stage companies focused on cancer care, aiming to improve patient outcomes and drive innovation in the field.
Format and cadence
- Event types
- pitch-night
- Recurrence
- annual
- Modality
- in-person
- Startups can present
- Yes
Availability
- Registration state
- Accepting
Audience and fit
- Selection criteria
- application
- Stages
- Pre-seed · Seed
- Audience
- Founders · Investors
- Regions
- United States
Speakers and past editions
Speakers
Key team members include Steve Curtis, PhD (Managing Director), Farnaz Bakhshi, PhD (Director, Innovation), and Eunice Chapon, JD (Director, Impact).
Past editions
The BEE Pitch Event connects oncology stakeholders with startup teams to facilitate investment and mentorship.
Capability profile
BrightEdge - American Cancer Society as a publisher
Editorial focus
BrightEdge focuses on investing in early-stage companies and technologies that provide patient-centric solutions in cancer care. Their investment strategy aims to advance scientific discovery, reduce health disparities, and build sustainability through strategic investments in technology-enabled solutions and science-based medicines.
Audience value
BrightEdge aims to catalyze scientific, social, and sustainable impact across the continuum of cancer care, generating financial returns that support the American Cancer Society's mission.
Format and cadence
- Content formats
- research-report
- Primary platform
- acsbrightedge.org
Availability
- Guest pitch state
- Not currently accepting
Audience and focus
- Audience
- Founders · Investors · Researchers
- Regions
- United States
Flagship work and coverage
Flagship properties
BrightEdge operates the ACS Impact Venture Fund (AIVF), a donor-funded fund that invests in early-stage, for-profit companies developing cancer-focused therapeutics, diagnostics, medical devices, and technologies.
Notable coverage
BrightEdge has been profiled on platforms such as cancer.org, prnewswire, and Dallas Innovates, highlighting their impact and investment activities.
Common questions
What to know about BrightEdge - American Cancer Society
Upseed classifies BrightEdge - American Cancer Society under the Venture Capital organization type. Its current public profile includes funder, event host, and publisher capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 22, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.